Eli Lilly and Company (LLY) Releases Updated Results from Phase 3 EMBER-3 Study of Inluriyo (imlunestrant)

Eli Lilly and Company (NYSE:LLY) is one of the Best Stocks to Invest in for the Next 3 Years. On December 12, Eli Lilly and Company (NYSE:LLY) released updated results from Phase 3 EMBER-3 study of Inluriyo (imlunestrant), which is an oral estrogen receptor antagonist, in patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer (MBC), whose disease progressed on a prior aromatase inhibitor (Al), with or without a CDK4/6 inhibitor.

Notably, after the recent FDA approval of Inluriyo as monotherapy, the updated data exhibit continued clinically meaningful benefit, both for patients receiving monotherapy and those receiving the combination with abemaciclib, as well as further strengthen its role in the treatment setting. Eli Lilly and Company (NYSE:LLY) announced that results for imlunestrant plus abemaciclib combination were consistent with previous efficacy results. Also, they demonstrated durable benefit throughout efficacy endpoints, irrespective of ESR1 mutation status.

In a separate release, on December 9, Eli Lilly and Company (NYSE:LLY) announced its plans to invest over $6 billion in new manufacturing facility in Huntsville, Alabama. The next-generation synthetic medicine active pharmaceutical ingredient (API) facility would be producing small molecule synthetic and peptide medicines.

Eli Lilly and Company (NYSE:LLY) highlighted that the site would be among those manufacturing orforglipron, its first oral, small molecule GLP-1 receptor agonist, which it plans to submit to global regulatory agencies for obesity by the year’s end.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now

Disclosure: None. This article is originally published at Insider Monkey.